Session Details

U062 Advances in Microneedling Techniques Around the World

Sun, Mar 9, 8:00 AM - 9:00 AM
W209C
1 CME Available Focus Session
View Map

DESCRIPTION

Open admission to eligible categories, no tuition or ticket

The session aims to present updated, evidence-based practices and clinical pearls with a global perspective, using microneedling and other needling procedures in a safe and effective way to manage various common dermatoses. Conditions to be reviewed may include scars of various etiologies, striae distensae, pigmentary dermatoses and rhytides. The use of microneedling to facilitate transdermal drug delivery will additionally be reviewed. Microneedling and radiofrequency microneedling will be compared and discussed. Topics to be presented will include assessment approaches, supporting recent literature, clinical pearls and experiences, and discussion of adverse effects and management options.

LEARNING OBJECTIVES

1.

Demonstrate the safe and effective use of microneedling in patients with various common dermatoses as performed in real-world clinical practice

2.

Evaluate evidence-based practices using microneedling (vs. radiofrequency microneedling) for scars, striae and rhytides based on clinical experience and research

3.

Formulate approaches and treatment plans that optimizes outcomes and minimize adverse effects, when targeting aesthetic and medical skin needs of patients using microneedling across the skin spectrum

SCHEDULE

12:00 PM

Introductions and Welcome

Monica Ka Yi Li, MD, FAAD, Tina S. Alster, MD, FAAD

12:05 PM

Practical use of microneedling for transdermal drug delivery: Insights from Korea

Boncheol Goo

12:18 PM

Microneedling and rejuvenation: Pearls from Thailand

Rungsima Wanitphakdeedecha, MD, IFAAD

12:31 PM

Use of Microneedling in Skin of Color: Treating hyperpigmented and hypertrophic scars

Robyn D. Siperstein, MD, FAAD

12:43 PM

Panel discussion and Q&A

SPEAKERS

Tina S. Alster, MD, FAAD

Tina S. Alster, MD, FAAD

Boncheol Goo

Boncheol Goo

Monica Ka Yi Li, MD, FAAD

Monica Ka Yi Li, MD, FAAD

Robyn D. Siperstein, MD, FAAD

Robyn D. Siperstein, MD, FAAD

Rungsima Wanitphakdeedecha, MD, IFAAD

Rungsima Wanitphakdeedecha, MD, IFAAD

SPEAKER DISCLOSURES

Tina S. Alster, MD, FAAD

A Method – Consultant(Other Financial Benefit); Hair Sanity – Stockholder(Stock); PhyNet Dermatology – Employee (w-2 relationship)(Salary);

Boncheol Goo

Agnes Medical – Board of Directors(Patent royalties or other compensation for Intellectual Property Rights); Classys – Advisory Board(Honoraria); Colgate-Palmolive – Advisory Board(Honoraria); Pharmaresearch – Advisory Board(Honoraria); Speclipse – Board of Directors(Stock Options);

Monica Ka Yi Li, MD, FAAD

AbbVie – Consultant(Honoraria); Bausch Health – Consultant(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Beiersdorf, Inc. – Consultant(Honoraria), Speaker(Honoraria); Candela Corporation – Consultant(Honoraria), Other(Equipment), Speaker(Honoraria); Endo Pharmaceuticals – Advisory Board(Honoraria); Galderma Canada, Inc – Speaker(Non-accredited CME Education Grant); Galderma Global – Advisory Board(Honoraria); Johnson and Johnson – Consultant(Honoraria); Kenvue – Advisory Board(Honoraria), Other(No Compensation Received); L'Oreal USA Inc. – Advisory Board(Honoraria), Consultant(Honoraria), Investigator(Grants/Research Funding); Merz Aesthetics – Speaker(Honoraria); Pfizer Inc. – Consultant(Honoraria), Speaker(Honoraria); Pierre Fabre – Speaker(Honoraria); Procter & Gamble Company – Consultant(Honoraria); Searchlight Pharma – Advisory Board(Honoraria); Shiseido, Inc. – Consultant(Honoraria); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria);

Robyn D. Siperstein, MD, FAAD

Allergan – Consultant (1099 relationship)(Fees); Allergan, Inc – Advisory Board(Fees), Investigator(Grants/Research Funding), Speaker/Faculty Education(Fees); Galderma USA – Advisory Board(Fees), Investigator(Grants/Research Funding), Speaker(Fees); Sciton Inc. – Speaker(Fees), Stockholder Private Company(Stock);

Rungsima Wanitphakdeedecha, MD, IFAAD

No financial relationships exist with ineligible companies.